Cover Image

Efficacy of switching to aripiprazole and ziprasidone on clinical and metabolic profile among schizophrenic patients with metabolic syndrome / Mas Ayu Binti Said

Introduction: Schizophrenia is a devastating mental illness that impairs mental and social functioning and often leads to the development of co-morbid diseases. They are at greater risk for metabolic dysfunctions than other individuals due to a number of reasons, including inactive lifestyle, poor d...

Full description

Saved in:
Bibliographic Details
Main Author: Mas Ayu, Said
Format: Thesis
Published: 2013
Subjects:
R Medicine (General)
RC0254 Neoplasms. Tumors. Oncology (including Cancer)
Online Access:http://studentsrepo.um.edu.my/5620/1/Formated_Thesis_6_May_2013.pdf
http://studentsrepo.um.edu.my/5620/
Tags: Add Tag
No Tags, Be the first to tag this record!
id my.um.stud.5620
record_format eprints
institution Universiti Malaya
building UM Library
collection Institutional Repository
continent Asia
country Malaysia
content_provider Universiti Malaya
content_source UM Student Repository
url_provider http://studentsrepo.um.edu.my/
topic R Medicine (General)
RC0254 Neoplasms. Tumors. Oncology (including Cancer)
spellingShingle R Medicine (General)
RC0254 Neoplasms. Tumors. Oncology (including Cancer)
Mas Ayu, Said
Efficacy of switching to aripiprazole and ziprasidone on clinical and metabolic profile among schizophrenic patients with metabolic syndrome / Mas Ayu Binti Said
description Introduction: Schizophrenia is a devastating mental illness that impairs mental and social functioning and often leads to the development of co-morbid diseases. They are at greater risk for metabolic dysfunctions than other individuals due to a number of reasons, including inactive lifestyle, poor dietary choices, and side effects of antipsychotic medications. Atypical antipsychotics were reported to be associated with increased risk of hyperglycaemia and hyperlipidemia, and subsequently increase the risk of metabolic syndrome. However, ziprasidone and aripiprazole have a favourable metabolic profile. Objectives: i) To determine the prevalence of metabolic syndrome and its components among schizophrenia patients. ii) To determine the improvement and reversibility of metabolic syndrome, its components and lipid profiles after switching to aripiprazole or ziprasidone. iii) To determine the safety and efficacy of aripiprazole and ziprasidone in the treatment of schizophrenia patients with metabolic syndrome. Methodology:Screening -The study was conducted at four mental institutions and four general hospitals. Study population were schizophrenia patients aged between 18 and 65 years old, who met the DSM-IV TR criteria for schizophrenia. Patients should receive antipsychotic treatment for at least 1 year and were not on mood stabilizer. Metabolic syndrome was defined by using the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) criteria-modified for Asian waist circumference. Randomized double-blind controlled trial was conducted for 6-month after screening.The dose of aripiprazole and ziprasidone, can be either increased or reduced based on clinical assessment. The total daily dosage of ziprasidone ranges from 80mg - 160mg.The total daily dosage of aripiprazole ranges from 10mg - 30 mg. The outcome measures included body mass index (BMI), waist circumference, blood v pressure(BP), fasting blood sugar (FBS) and lipid profile, adverse effects monitoring and clinical rating scale such as Positive and Negative Symptoms Scale (PANSS), Clinical Global Impression Scale (CGI), Abnormal Involuntary Movement Scale (AIMS), Barnes Akathasia Scale (BAS) and Simpson Angus Scale (SAS).Intention-to-treat analysis and mixed-effects model with repeated measures (MMRM) for statistical analysis were done. Results: A total of 527 patients were screened but only 270 schizophrenia patients fulfil all inclusion and did not have any exclusion criteria. The prevalence of metabolic syndrome was 46.7%. There was improvement in the prevalence of all metabolic syndrome component from baseline to 6-month after switching to aripiprazole or ziprasidone; waist circumference (aripiprazole 84.4% vs. 44.4%, ziprasizone 87.1% vs. 35.3%), HDL cholesterol (aripiprazole 54.4% vs. 33.3%, ziprasizone 52.9% vs. 23.5%), triglycerides (aripiprazole 50.0% vs. 21.1%, ziprasizone 37.6% vs. 12.9%), BP (aripiprazole 41.1% vs. 25.6%, ziprasizone 32.9% vs. 20.0%), FBS (aripiprazole 42.2% vs. 20.0%, ziprasizone 25.9% vs. 8.2%, p<0.05). Switching to either aripiprazole or ziprasidone cause statistically significant reduction in prevalence of metabolic syndrome after 6 month of treatment (aripiprazole 58.9% vs. 30.0%, ziprasizone 51.8% vs. 15.3%, p<0.05). There was statistically significant improvement in PANSS, CGI, BARS and SAS after switching to aripiprazole or ziprasidone. Conclusion: The prevalence of metabolic syndrome in schizophrenia patients receiving antipsychotic in Malaysia was very high. Switching to aripiprazole or ziprazidone was effective in reversing the metabolic syndrome and its components among schizophrenia patients who had metabolic syndrome.
format Thesis
author Mas Ayu, Said
author_facet Mas Ayu, Said
author_sort Mas Ayu, Said
title Efficacy of switching to aripiprazole and ziprasidone on clinical and metabolic profile among schizophrenic patients with metabolic syndrome / Mas Ayu Binti Said
title_short Efficacy of switching to aripiprazole and ziprasidone on clinical and metabolic profile among schizophrenic patients with metabolic syndrome / Mas Ayu Binti Said
title_full Efficacy of switching to aripiprazole and ziprasidone on clinical and metabolic profile among schizophrenic patients with metabolic syndrome / Mas Ayu Binti Said
title_fullStr Efficacy of switching to aripiprazole and ziprasidone on clinical and metabolic profile among schizophrenic patients with metabolic syndrome / Mas Ayu Binti Said
title_full_unstemmed Efficacy of switching to aripiprazole and ziprasidone on clinical and metabolic profile among schizophrenic patients with metabolic syndrome / Mas Ayu Binti Said
title_sort efficacy of switching to aripiprazole and ziprasidone on clinical and metabolic profile among schizophrenic patients with metabolic syndrome / mas ayu binti said
publishDate 2013
url http://studentsrepo.um.edu.my/5620/1/Formated_Thesis_6_May_2013.pdf
http://studentsrepo.um.edu.my/5620/
_version_ 1738505812993638400
spelling my.um.stud.56202015-06-24T01:19:26Z Efficacy of switching to aripiprazole and ziprasidone on clinical and metabolic profile among schizophrenic patients with metabolic syndrome / Mas Ayu Binti Said Mas Ayu, Said R Medicine (General) RC0254 Neoplasms. Tumors. Oncology (including Cancer) Introduction: Schizophrenia is a devastating mental illness that impairs mental and social functioning and often leads to the development of co-morbid diseases. They are at greater risk for metabolic dysfunctions than other individuals due to a number of reasons, including inactive lifestyle, poor dietary choices, and side effects of antipsychotic medications. Atypical antipsychotics were reported to be associated with increased risk of hyperglycaemia and hyperlipidemia, and subsequently increase the risk of metabolic syndrome. However, ziprasidone and aripiprazole have a favourable metabolic profile. Objectives: i) To determine the prevalence of metabolic syndrome and its components among schizophrenia patients. ii) To determine the improvement and reversibility of metabolic syndrome, its components and lipid profiles after switching to aripiprazole or ziprasidone. iii) To determine the safety and efficacy of aripiprazole and ziprasidone in the treatment of schizophrenia patients with metabolic syndrome. Methodology:Screening -The study was conducted at four mental institutions and four general hospitals. Study population were schizophrenia patients aged between 18 and 65 years old, who met the DSM-IV TR criteria for schizophrenia. Patients should receive antipsychotic treatment for at least 1 year and were not on mood stabilizer. Metabolic syndrome was defined by using the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) criteria-modified for Asian waist circumference. Randomized double-blind controlled trial was conducted for 6-month after screening.The dose of aripiprazole and ziprasidone, can be either increased or reduced based on clinical assessment. The total daily dosage of ziprasidone ranges from 80mg - 160mg.The total daily dosage of aripiprazole ranges from 10mg - 30 mg. The outcome measures included body mass index (BMI), waist circumference, blood v pressure(BP), fasting blood sugar (FBS) and lipid profile, adverse effects monitoring and clinical rating scale such as Positive and Negative Symptoms Scale (PANSS), Clinical Global Impression Scale (CGI), Abnormal Involuntary Movement Scale (AIMS), Barnes Akathasia Scale (BAS) and Simpson Angus Scale (SAS).Intention-to-treat analysis and mixed-effects model with repeated measures (MMRM) for statistical analysis were done. Results: A total of 527 patients were screened but only 270 schizophrenia patients fulfil all inclusion and did not have any exclusion criteria. The prevalence of metabolic syndrome was 46.7%. There was improvement in the prevalence of all metabolic syndrome component from baseline to 6-month after switching to aripiprazole or ziprasidone; waist circumference (aripiprazole 84.4% vs. 44.4%, ziprasizone 87.1% vs. 35.3%), HDL cholesterol (aripiprazole 54.4% vs. 33.3%, ziprasizone 52.9% vs. 23.5%), triglycerides (aripiprazole 50.0% vs. 21.1%, ziprasizone 37.6% vs. 12.9%), BP (aripiprazole 41.1% vs. 25.6%, ziprasizone 32.9% vs. 20.0%), FBS (aripiprazole 42.2% vs. 20.0%, ziprasizone 25.9% vs. 8.2%, p<0.05). Switching to either aripiprazole or ziprasidone cause statistically significant reduction in prevalence of metabolic syndrome after 6 month of treatment (aripiprazole 58.9% vs. 30.0%, ziprasizone 51.8% vs. 15.3%, p<0.05). There was statistically significant improvement in PANSS, CGI, BARS and SAS after switching to aripiprazole or ziprasidone. Conclusion: The prevalence of metabolic syndrome in schizophrenia patients receiving antipsychotic in Malaysia was very high. Switching to aripiprazole or ziprazidone was effective in reversing the metabolic syndrome and its components among schizophrenia patients who had metabolic syndrome. 2013 Thesis NonPeerReviewed application/pdf http://studentsrepo.um.edu.my/5620/1/Formated_Thesis_6_May_2013.pdf Mas Ayu, Said (2013) Efficacy of switching to aripiprazole and ziprasidone on clinical and metabolic profile among schizophrenic patients with metabolic syndrome / Mas Ayu Binti Said. PhD thesis, University of Malaya. http://studentsrepo.um.edu.my/5620/
score 13.211869

Similar Items